Results 1 to 10 of about 6,040 (212)
Rimonabant: From RIO to Ban [PDF]
Journal of Obesity, 2011 Endocannabinoid antagonism as a treatment for obesity and the metabolic syndrome became a hugely anticipated area of pharmacology at the start of the century. The CB1 receptor antagonist Rimonabant entered the European mass market on the back of several
Amir H. Sam +2 more
doaj +4 more sources
Rimonabant for treating tobacco dependence
Vascular Health and Risk Management, 2007 Michael B Steinberg1,2, Jonathan Foulds11University of Medicine and Dentistry of New Jersey–School of Public Health, Tobacco Dependence Program, New Brunswick, NJ, USA; 2University of Medicine and Dentistry of New Jersey–Robert Wood Johnson ...
Michael B Steinberg, Jonathan Foulds
doaj +3 more sources
Influence of rimonabant treatment on peripheral blood mononuclear cells; flow cytometry analysis and gene expression profiling [PDF]
PeerJ, 2015 The cannabinoid receptor type 1 (CB1) antagonist rimonabant has been used as treatment for obesity. In addition, anti-proliferative effects on mitogen-activated leukocytes have been demonstrated in vitro.
Stefan Almestrand +7 more
doaj +3 more sources
Melancholic features related to rimonabant [PDF]
General Hospital Psychiatry, 2009 Obesity is currently considered a global epidemic and its prevention and treatment is a major public health concern, demanding treatment which may combine a sociocultural approach, lifestyle modification, nutritional, pharmacological or surgical strategies.
Bernardo, de Mattos Viana +2 more
openaire +3 more sources
Vascular Health and Risk Management, 2007 Kirk A Bronander1, Michael J Bloch21Division of General Internal Medicine, 2Divisions of Cardiology and General Internal Medicine, Department of Medicine, University of Nevada School of Medicine, Reno, NV, USAAbstract: The endocannabinoid system (ECS) is
Kirk A Bronander, Michael J Bloch
doaj +2 more sources
Rimonabant-induced depression in schizophrenia
Indian Journal of Psychiatry, 2014 Sir, Cannabinoids modulate mood probably through serotonergic neurons in medial prefrontal cortex and cannabinoid receptor (CB1) receptor antagonists may reverse these effects.
Arasappa, Rashmi +6 more
openaire +3 more sources
Interfering with reconsolidation by rimonabant results in blockade of heroin-associated memory [PDF]
Frontiers in PharmacologyDrug-associated pathological memory remains a critical factor contributing to the persistence of substance use disorder. Pharmacological amnestic manipulation to interfere with drug memory reconsolidation has shown promise for the prevention of relapse ...
Jiang Lin +11 more
doaj +2 more sources
Journal of the American College of Cardiology, 2006 Rimonabant is a first selective blocker of the cannabinoid receptor type 1 (CB1) being developed for the treatment of multiple cardiometabolic risk factors, including abdominal obesity and smoking.
Christopher P Cannon
exaly +2 more sources
Rimonabant for the Treatment of Obesity
Recent Patents on Cardiovascular Drug Discovery, 2008 Obesity is a growing public health problem that is already reaching epidemic proportions and is increasingly encompassing young children and adolescents. Despite the increasing prevalence and the health risks associated with obesity, the pharmacotherapeutic options for treating obesity are limited. The endogenous cannabinoid or endocan-nabinoid system (
Ashish, Samat +3 more
openaire +3 more sources
Pharmacological inhibition of the CB1 cannabinoid receptor restores abnormal brain mitochondrial CB1 receptor expression and rescues bioenergetic and cognitive defects in a female mouse model of Rett syndrome [PDF]
Molecular AutismBackground Defective mitochondria and aberrant brain mitochondrial bioenergetics are consistent features in syndromic intellectual disability disorders, such as Rett syndrome (RTT), a rare neurologic disorder that severely affects mainly females carrying
Livia Cosentino +14 more
doaj +2 more sources